By 1970 the administration of aluminium hydroxide and/or calcium carbonate as phosphate binders in dialysis patients was virtually universal practice. In 1972, Alfrey was one of the first to ...

To evaluate the efficacy of calcium carbonate as an alternative phosphate binder, we studied 20 patients maintained on dialysis during three consecutive periods. In period 1, the patients took ...

The FDA has started a review of Unicycive Therapeutics' drug for hyperphosphataemia in patients with chronic kidney disease ...

Shandong Xinhua Pharmaceutical Company Limited Class H (HK:0719) has released an update. Shandong Xinhua Pharmaceutical ...

These sessions are incredibly taxing for patients and caregivers, both physically and mentally. Unfortunately, dialysis doesn’t remove enough phosphorus from the blood for most patients. As a result, ...

on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. Eighty percent of patients with CKD on ...

More information: Shoya Mori et al, Estimated Proximal Tubule Fluid Phosphate Concentration and Renal Tubular Damage Biomarkers in Early Stages of Chronic Kidney Disease, Journal of Renal ...

UNI-494 is targeting acute kidney injury (AKI), a challenging and often under-treated disease ... In the survey, OLC ...

leading to phosphorus buildup in people with chronic kidney disease. High phosphorus levels pull calcium out of the bones, weakening bone structure. Elevated phosphorus levels can also result in ...